Home MarketSun Pharma Advanced Research Company Ltd.

Sun Pharma Advanced Research Company Ltd. Stock Info: As on 2018-02-22 15:58:19

Nse

432.30

12.65(3.01%)
Change%
52 Week Range
272.00
30.00
532.00
12.00
Open420.90
Day's Range335.72 - 503.58
Value Traded (in ₹ Cr.) 11.40

Bse

430.45

10.65(2.54%)
Change %
52 Week Range
273.00
29.00
532.40
12.00
Open422.70
Day's Range335.84 - 503.76
Value Traded (in ₹ Cr.) 2.40

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 169,296,119.00 67.47%
Mutual Funds/UTI 5,234,625.00 2.09%
FII 16,820,216.00 6.70%
Employee 0.00 0.00%
Public 35,161,447.00 14.01%
Government 0.00 0.00%
Others 24,316,031.00 9.69%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 42.26
Basic EPS (Rs.) -2.96
Cash EPS -2.64
BVPerShare Excl 1.26
Operating Revenue 6.81
PBDITPerShare -2.55
Dividend 0.00
NPPerShare -2.96
Current Ratio 0.53
Quick Ratio 0.53
PriceToBV 227.93
Earnings -0.01
PBDIT Margin -37.36
PBT Margin -43.39
NP Margin -43.39
Return On Assets -43.02
Retention Ratios 0.00
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 164.22
Total Expenses 234.21
EBITDA -60.26
PBT -69.99
PAT -69.99
Net Income -69.99
More
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 77.59
Total Expenses 126.24
EBITDA -52.52
PBT -50.60
PAT -50.60
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 23.67
Net worth 29.90
Investments 0.00
Total Liability 162.66
Total debt 55.20
Net block 70.83
Total Assets 162.66
Parameter Mar-16 (₹ Cr.) 6M % change
Total share capital 23.67
Net worth 29.90
Investments 0.00
Total Liability 162.66
Total debt 55.21
Net block 70.83
Total Assets 162.66
Company Curr Price Prev. Close Change% W's Low/High

Adani Ports & Special Economic Zone Ltd.

404 395.6 2.12
387.2415.6

Banaras Beads Ltd.

67.9 65.1 4.3
61.1568.35

Binani Industries Ltd.

103.95 107.15 -2.99
103.5114.8

Career Point Ltd.

124.35 123.55 0.65
122.35134.6

Delta Corp Ltd.

348.9 352.2 -0.94
347386.4

Dredging Corporation Of India Ltd.

689 686.95 0.3
678.75723.8

Future Consumer Ltd.

60.25 59.9 0.58
58.1563.45
Company Curr Price Prev. Close Change% W's Low/High

Adani Ports & Special Economic Zone Ltd.

404.1 395.55 2.16
387.4417

Alpha Hi-Tech Fuel Ltd.

0.87 0.91 -4.39
0.870.87

Anil Ltd.

28.9 30.4 -4.93
28.928.9

Bagalkot Udyog Ltd.

23.9 25.15 -4.97
23.923.9

Banaras Beads Ltd.

68.15 65 4.85
61.568.15

Binani Industries Ltd.

104 107.5 -3.26
103.5113.5

Brahmanand Himghar Ltd.

4.08 4.29 -4.9
4.084.08
More
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities 44.21
Cash from investing activities 13.08
Cash from financing activities -50.55
Net change in cash 6.63

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
UTI Mid Cap Fund 1.47%
Axis Focused 25 Fund 1.78%
Axis Long Term Equity Fund 0.27%
UTI Opportunities Fund 0.56%
DSP BlackRock Micro-Cap Fund 0.32%
UTI Long Term Advantage Fund - Series III 3.53%

Enough assets to meet any liability, says scam-hit PNB

PNB said it has followed lawful avenues to recover its dues following Rs 11,400 crore swindling of funds allegedly by jewellery designer Nirav Modi and associates, reported PTI. The country's second largest public sector lender also reaffirmed that it has enough assets to meet any liability. We have followed lawful avenues available to us as per law of the land to recover our dues, the bank said in a regulatory filing. Stock exchanges had sought clarification on Modi's comment that PNB has closed all options to recover dues by going public. The bank had disclosed about the scam on February 14 through a regulatory filing. On why it did not inform stock exchanges about the filing of FIR with CBI at the occurrence of the event, PNB said: Since law enforcing agencies were assigned to investigate the matter, any news in public would have altered the fraudster, affecting recovery. The bank said on basis of preliminary investigation report, it had simultaneously informed its Board and BSE, NSE of initial fraud case of Rs 280.7 crore. Upon receiving further investigation report enhancing the fraud amount to Rs 11,394 crore, FMR (Fraud Monitoring Return) with RBI, FIR with CBI were filed in the evening of February 13, 2018, and BSE and NSE were informed on February 14 around 9 am, the bank said. About the impact of the scam on the financials and operations of the bank, it said: We have enough assets/ capital to meet any liability which is decided as per law.

22-02-2018 16:37

Merck board recommends dividend

Merck on Thursday said that its board has announced a dividend at the rate of Rs 15 per equity share. “The board of directors of the company at its meeting held on February 22, 2018, has recommended payment of dividend at the rate of Rs 15 per equity share of Rs 10 each for the year ended December 31, 2017,” Merck said in a filing to the Bombay Stock Exchange. Meanwhile, shares of company closed day’s trade at Rs 1443.90 apiece, down 0.92 per cent, on the Bombay Stock Exchange.

22-02-2018 16:35

Sanofi board recommends final dividend

Sanofi India on Thursday said that its board has recommended a final dividend of Rs 53 per equity share of Rs 10 for the year ended December 31, 2017. “An interim dividend of Rs 18 per equity share of Rs 10 was paid in August 2017. The interim dividend and the proposed final dividend totalling to Rs 71 per equity share of Rs 10, will together amount to a distribution of Rs 1,633 million (excluding dividend distribution tax),” Sanofi India said in a filing to the Bombay Stock Exchange. Meanwhile, shares of company closed day’s trade at Rs 4833.20 apiece, down 0.10 per cent, on the Bombay Stock Exchange.

22-02-2018 16:34

BSE signs pact with Soybean Processors Association of India

BSE signed a pact with Soybean Processors Association of India (SOPA) for the growth and development of commodity market and its value-chain participants, enabling them to manage price risk in a better manner in the soyabean oil complex, reported PTI. The agreement will be beneficial for launching products like soybean, soyoil and soymeal futures trading on BSE, the exchange said in a statement issued here. BSE and SOPA have made significant progress in their respective areas for the growth and development of the commodity market and will share knowledge and expertise in this regard, the it added. BSE MD and CEO Ashishkumar Chauhan said, BSE and SOPA fully acknowledge each other's respective strengths, resources, experience and expertise and therefore feel it expedient to join hands for mutual benefits in pursuit of common goals with the underlying objective of developing commodity derivatives market. BSE (formerly Bombay Stock Exchange), established in 1875, is Asia's oldest stock exchange, while SOPA is the only national-level body representing the soybean processors, farmers, exporters and brokers in India working towards strengthening soybean as a viable crop. Last month, BSE conducted mock-trading for commodity derivatives segment as it prepares itself for the launch of trade in such products. The platform currently offers trading in equities, equity derivatives as well as currency derivatives.

22-02-2018 16:25

Sundaram Equity Plus: change in investment factsheets for January

Sundaram Equity Plus has announced change in investment factsheets and fund flash for the month ended January 31, 2018. As on Jan 31, 2018, the total size of the Fund was Rs 42.22 crores, compared with Rs 41.16 crores in the last month. The Fund's NAV per unit was Rs 15.65 for Growth, while 52-Week High and Low ranges were Rs 16.37 and Rs 13.92 respectively. The Equity - Diversified fund with Growth plan was launched on May 04, 2011 and managed by Fund Manager Rahul Baijal. The top five companies based on a percentage of total holdings were HDFC Bank Ltd (2.41 Cr.), Housing Development Finance Corporation Ltd (2.15 Cr.), Reliance Industries Ltd (2.11 Cr.), ICICI Bank Ltd (2.10 Cr.) and Infosys Ltd (1.98 Cr.). Sundaram Equity Plus is promoted by Sundaram Mutual Fund and managed by Sundaram Asset Management Company Ltd..

22-02-2018 15:30

Sun Pharma Advanced posts Q3 net loss of Rs 58.07 cr

The company reported standalone net loss during the quarter stood at Rs 58.07 crore as compared to net loss of Rs 66.33 crore in the previous year quarter. Net revenue of the company declined moderately by 15.75 per cent at Rs 19.42 crore in October-December quarter of this fiscal as against Rs 23.05 crore in the corresponding period last year. During October-December quarter, operating expenses dropped by 13.90 per cent to Rs 77.59 crore from Rs 90.12 crore in year ago period. Other Income dipped by 25.17 per cent at Rs 2.14 crore versus (Dec'16 Rs 2.86 crore). Operating Profit slipped by 13.27 per cent to Rs -58.17 crore as against Rs -67.07 crore in the year ago period, while Operating Profit Margin (OPM) contracted year-on-year to 2.94 per cent in December quarter. Interest declined by 33.33 per cent y-o-y to Rs 0.02 crore

01-Feb-2018 11:28 AM

Sun Pharma Advanced - Financial Result Updates

Sun Pharma Advanced Research Company Limited has submitted to the Exchange, the financial results for the period ended December 31, 2017.

29-Jan-2018 02:14 PM

Sun Pharma Advanced - Outcome Of Board Meeting Dated 29Th January 2018

The Board of Directors of the Company at their meeting held from 12:00 Noon to 02:00 pm today, inter alia, took on record and duly approved the Un-audited financial results of the Company for the quarter and nine months ended 31st December 2017 which is enclosed herewith along with the Limited Review Report of the Statutory Auditors thereon as Annexure I.

This is for your information and record.

29-Jan-2018 02:12 PM

Sun Pharma Advanced - Shareholding for the Period Ended December 31, 2017

Sun Pharma Advanced Research Company Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2017.

16-Jan-2018 09:57 AM

Sun Pharma Advanced - Board Meeting On 29Th January 2018

Pursuant to regulation 29 (1) of the SEBI (Listing obligation & Disclosure Requirements) Regulation, 2015, we hereby inform you that a meeting of the Board of Directors of Sun Pharma Advanced Research Company Limited will be held on Monday, 29th January, 2018, inter alia, to consider and take on record, the unaudited financial results of the Company for the quarter and nine months ended 31st December 2017.

Further, kindly note that pursuant to the Company's Code of Internal Procedures and Code of Conduct for Prevention of Insider Trading, the trading window for trading by designated persons shall be closed from Wednesday, 17th January 2018 to Wednesday, 31st January, 2018 (both days inclusive) in view of the above.

15-Jan-2018 04:38 PM

Sun Pharma Advanced - Outcome Of Board Meeting Dated 29Th January 2018

The Board of Directors of the Company at their meeting held from 12:00 Noon to 02:00 pm today, inter alia, took on record and duly approved the Un-audited financial results of the Company for the quarter and nine months ended 31st December 2017 which is enclosed herewith along with the Limited Review Report of the Statutory Auditors thereon as Annexure I.

This is for your information and record.

29-Jan-2018 02:12 PM

Sun Pharma Advanced - Shareholding for the Period Ended December 31, 2017

Sun Pharma Advanced Research Company Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2017.

16-Jan-2018 09:57 AM

Sun Pharma Advanced - Board Meeting On 29Th January 2018

Pursuant to regulation 29 (1) of the SEBI (Listing obligation & Disclosure Requirements) Regulation, 2015, we hereby inform you that a meeting of the Board of Directors of Sun Pharma Advanced Research Company Limited will be held on Monday, 29th January, 2018, inter alia, to consider and take on record, the unaudited financial results of the Company for the quarter and nine months ended 31st December 2017.

Further, kindly note that pursuant to the Company's Code of Internal Procedures and Code of Conduct for Prevention of Insider Trading, the trading window for trading by designated persons shall be closed from Wednesday, 17th January 2018 to Wednesday, 31st January, 2018 (both days inclusive) in view of the above.

15-Jan-2018 04:38 PM

Corporate Details

About Management

2007 - Sun Pharma Advanced Research Co.Ltd was formed in the year 2007, with separation of India's leading specialty pharma company, Sun Pharmaceutical Industries Ltd, and its active projects in drug discovery and innovation into a new company. The parent company, Sun Pharma Industries Ltd continues to invest independently in generic research. - Sun Pharma Advanced Research Company Ltd (SPARCL) had allotted 3,39,441 equity shares of Re 1 each to the bond-holders of Sun Pharma Industries Ltd (SPIL) on conversion of 5,500 foreign currency convertible bonds upon conversion. - Balance Sheet along with the Profit and Loss Account for the year ended March 31, 2007 adopted and the Reports of Directors & Auditors thereon. - Mr. Dilip S Shanghvi and Mr. Sudhir V Valia, re appointed as the Directors of the Company. - According to the clause 10.2 of the scheme of arrangement of demerger, sanctioned by the High Court of Gujarat through its order dated March 01, 2007, issued on March 28, 2007 and as per supplementary Trust Deed dated may 18, 2007, the FCCB's holders of Sun Pharma Industries Ltd, are entitled for one equity share of Re 1 each of the company for every equity share of Rs.5 each of SPIL. 2011 - "Sun Pharma announces USFDA approval for DOCEFREZ (docetaxel) for Injection". 2012 -SPARC - Starhaler Device finalist at Medical Design Excellence Awards -Sun Pharma Advanced Research Company Ltd Issues Rights in the Ratio of 1:7 2013 -SPARC to provide update on NCE & NDDS programs 2014 -SPARC Announces India Approval for Paclitaxel Injection Concentrate for Nanodispersion (PICN)

Registered Office

17-B, Mahal Industrial Estate, Mahakali Caves Road, Andheri (East)

,,,      ,

Registrar Details

Link Intime India Pvt. Ltd.